Skip to main content

Advertisement

Table 1 Patient demographics and baseline disease characteristics

From: Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Parameters n = 15
Gender (female/male) 13/2
Age (years) 49 (33–73)
Median years post-diagnosis 2.9 (1–16)
Ocular symptoms 15 (100%)
Schirmer-I test (mm) 12 ± 12
Oral symptoms 15 (100%)
Unstimulated salivary flow (ml/minute) 0.07 ± 0.13
Moderate-to-severe fatigue 13 (87%)
Fatigue VAS (mm) 56 ± 22
Focus score ≥ 1 12 (80%)
Anti-Ro antibodies 12 (80%)
Anti-La antibodies 11 (73%)
ESR (mm/hour) 33 ± 15
IgG (mg/dl) 2,114 ± 934
  1. ESR, erythrocyte sedimentation rate; Ig, immunoglobulin; VAS, visual analogue scale.